Controlled trials support a specific HIV-associated lipodystrophy application, not a general promise of weight loss or rejuvenation.
Tesamorelin is the active substance in EGRIFTA medicines. The 2025 EGRIFTA WR US label specifies reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It explicitly excludes general weight-loss management. The indication matters because evidence about a defined clinical problem is often repackaged online as a broad body-composition claim. Begin with the condition and product under assessment rather than assuming that an approved ingredient has been approved for every advertised use.
The 2007 NEJM study randomised 412 people with HIV and abdominal fat accumulation for 26 weeks. Its primary endpoint was change in visceral adipose tissue measured by CT. That measure fell by 15.2% with tesamorelin and rose by 5.0% with placebo. This describes a particular fat compartment and study population. It does not mean participants lost 15.2% of total body weight, and the distinction should remain visible wherever the result is quoted.
Preparing the full guide…
The extended sections are available during your one-minute preview and with free email registration.
- A second randomised study adds replication
- Visceral fat, scale weight and appearance are different outcomes
- Liver-fat research asks an additional question
- The endocrine effect also creates safety questions
- An ingredient name is not a formulation bridge
- Questions that make a clinical conversation more useful
Sources & further reading
Sources support specific statements, not every possible use of a molecule. Echo hub articles provide research background; original publications and official guidance are identified where supplied.
- FDA — EGRIFTA WR prescribing information, revised March 2025
- Falutz et al. — Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV, NEJM (2007)
- Falutz et al. — Randomised tesamorelin trial with safety extension (2010)
- Stanley et al. — Tesamorelin, visceral fat and liver fat: a randomised clinical trial, JAMA (2014)